LY 517717

Drug Profile

LY 517717

Alternative Names: LY517717

Latest Information Update: 06 Apr 2011

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Eli Lilly
  • Class Anticoagulants; Antithrombotics; Piperazines
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Stroke; Thromboembolism; Thrombosis

Most Recent Events

  • 31 Jul 2008 Preclinical trials in Stroke in USA (PO)
  • 12 Dec 2007 Clinical development is ongoing
  • 12 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the adverse events and Thromboses therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top